AnaptysBio (NASDAQ:ANAB) Price Target Raised to $85.00

AnaptysBio (NASDAQ:ANAB) had its price objective boosted by Stifel Nicolaus from $56.00 to $85.00 in a report released on Thursday morning, Marketbeat.com reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Truist Financial raised their target price on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, January 21st. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Wedbush restated an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research report on Monday, November 24th. Finally, Barclays upped their target price on AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $73.44.

AnaptysBio Price Performance

ANAB opened at $55.41 on Thursday. The firm has a fifty day moving average price of $50.27 and a 200 day moving average price of $39.16. AnaptysBio has a 1 year low of $15.32 and a 1 year high of $63.47. The stock has a market cap of $1.59 billion, a P/E ratio of -106.56 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Monday, March 9th. The biotechnology company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. The company had revenue of $108.25 million during the quarter, compared to analysts’ expectations of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. Equities analysts expect that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio declared that its board has authorized a stock repurchase program on Friday, November 21st that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Insider Activity at AnaptysBio

In related news, CFO Dennis Mulroy sold 15,725 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $44.85, for a total value of $705,266.25. Following the transaction, the chief financial officer directly owned 9,401 shares of the company’s stock, valued at approximately $421,634.85. This trade represents a 62.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Magda Marquet sold 11,000 shares of AnaptysBio stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $48.23, for a total value of $530,530.00. Following the completion of the sale, the director owned 9,930 shares in the company, valued at approximately $478,923.90. The trade was a 52.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 156,280 shares of company stock valued at $7,254,939. 33.50% of the stock is owned by corporate insiders.

Institutional Trading of AnaptysBio

Several large investors have recently made changes to their positions in ANAB. Vanguard Group Inc. raised its stake in AnaptysBio by 4.5% in the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock valued at $74,855,000 after purchasing an additional 67,048 shares during the last quarter. State Street Corp lifted its holdings in AnaptysBio by 20.6% in the 4th quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock valued at $51,072,000 after purchasing an additional 180,042 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after purchasing an additional 822,975 shares during the last quarter. 683 Capital Management LLC boosted its stake in AnaptysBio by 18.5% during the 4th quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock worth $31,420,000 after purchasing an additional 101,093 shares during the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of AnaptysBio during the fourth quarter worth $21,559,000.

Trending Headlines about AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and kept a buy rating — a sizable upside vs. recent levels that likely boosted investor demand. Stifel raises PT to $85
• Positive Sentiment: Coverage noting a profitability turnaround and continued progress collecting Jemperli royalties supports a higher valuation narrative for ANAB. This fundamental story likely underpins recent buying interest. Assessing AnaptysBio valuation after profitability turnaround
• Positive Sentiment: ANAB hit a new 12‑month high following analyst upgrades, which can attract momentum and technical buying. ANAB hits new 12‑month high on analyst upgrade
• Negative Sentiment: HC Wainwright issued a mixed set of estimate changes: it lowered near‑term FY2026 and Q1/Q2 EPS forecasts (worse near‑term profitability) even as it raised several multi‑year estimates; the negative near‑term revisions could pressure sentiment despite the firm’s buy rating and $66 target. HC Wainwright estimate changes (MarketBeat summary)
• Neutral Sentiment: Short‑interest entries in recent reports are inconsistent/zero (showing NaN increases), indicating unreliable short‑interest data — not a clear driver of today’s move. (No reliable link provided in the filings.)

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.